While industry research isn’t flawless, or anything close, much of the critique industry faces – on subjects ranging from data transparency to subgroup analysis – reflect problems facing medical science as a whole, and responsibly should be viewed in that context. Read More...
Does digital health need to create robust, stand-alone enterprises in order to be successful, impactful, or funded? Read More...
Posted to
News
by
Health. Care.
on
Wed, Oct 10 2012
Filed under:
Filed under: health, Pharma & Healthcare, Innovation & Science, byline=David Shaywitz, ticker=NASDAQ:GOOG, ticker=NASDAQ:FB, ticker=NASDAQ:MSFT, ticker=NASDAQ:INTC, ticker=NASDAQ:ORCL, Exit Strategy
Most VC returns are generated by a handful of firms - the same firms year after year. Does this reflect proprietary knowledge, as a top VC asserts -- or is something else going on? Read More...
Posted to
News
by
Health. Care.
on
Tue, Oct 2 2012
Filed under:
Filed under: Pharma & Healthcare, Innovation & Science, byline=David Shaywitz, Management, VC, Intelligent Investing, venture capital, Kauffman Foundation, Nassim Taleb, Benchmark Capital
If reports of reawakening LP interest in health-focused VCs are true, digital medicine will benefit from the experience of investors with deep understanding of the healthcare system. Read More...
In exception-dominated fields such as startups and drug development, the magnitude of the rare success is virtually impossible to predict. Read More...
Recent content that I've seen and you may like. Read More...
Digital health can redefine medicine -- but will benefit from a wider ranger of investors, including those with deep healthcare expertise. Read More...
Esther Dyson and Dave McClure are prototypical examples of the VC as auteur. Read More...
Turning ideas into useful application is a key challenge in medical science and in digital health. Read More...
Industrialization isn't always the right answer -- just look at big pharma R&D. Read More...
In the current issue of The New Yorker, surgeon Atul Gawande provocatively suggests that medicine needs to become more like The Cheesecake Factory – more standardized, better quality control, with a touch of room for slight customization and innovation. The basic premise, of course, isn’t new, and seems...
To drive research into application, academic medical centers should recognize and cultivate translational innovators, and the start-ups they help build. Read More...
Posted to
News
by
Health. Care.
on
Thu, Aug 2 2012
Filed under:
Filed under: health, Pharma & Healthcare, Innovation & Science, byline=David Shaywitz, Innovation, UCSF, Rock Health, translational research, entrepreneur, digital health, Startups, academic medical center
In a recent post, I discussed the painful honestly of Silicon Valley tech VC Dave McClure’s much-discussed meditation, “Late Bloomer, Not a Loser.” I’ve since had a chance to read more about McClure’s unconventional investing philosophy, reflected in his firm, 500 Startups, and the approach seemed worth...
After toiling in humble obscurity for over 200 years, it seems the good folks at Massachusetts General Hospital finally have something to celebrate: a “Number 1” ranking on US News and World Reports (USNWR) latest “Best Hospital” list. And celebrate they did – with a confetti-laden duck-boat parade around...
As a recent arrival to Silicon Valley and its unique culture, I’ve had the unique opportunity to consider how it contrasts with the culture of medicine, with which I’m deeply familiar. I’ve been especially struck by the excessively reductive view many Silicon Valley engineers seem to have of medicine...